HIV,AIDS. Human immunodeficiency virus [HIV] disease
Conditions
Interventions
Intervention 1: Intervention group: Powder (condensed milk powder) MPC will receive 25 grams per day for 8 weeks. Intervention 2: Control group: They will receive 25 grams of Malto Dextrin sachet for
Sponsors
Esfahan University of Medical Sciences
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate with the project- CD4 level less than 500 - Patients with AIDS whose type of disease is fully confirmed through a complete medical examination and laboratory. Only patients with AIDS who have been on antiviral therapy for three months and are also on a consistent medication regimen should be included in this study.
Exclusion criteria
Exclusion criteria: Use of protein supplements Drug useAlcohol, acetylcysteine, NSAIDs three months before the study Sensitivity to dairy products Do not take calcium supplements or any product containing it Drugs or supplements that affect the immune and inflammatory systems, such as antioxidants, sexing, omega 3, curcumin People who, in addition to AIDS, suffer from other diseases that have oxidative stress as their etiology. Including: metabolic syndrome, diabetic foot ulcer, coronary artery disease, lung infection. Patients with clinical conditions that pose a serious health risk, including severe kidney, liver, thyroid and parathyroid disease, gastrointestinal and heart disease and cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anthropometric evaluation. Timepoint: Beginning and end of the study. Method of measurement: Using tape measure and scales.;Evaluation of safety indicators. Timepoint: Beginning and end of the study. Method of measurement: CD4, CD8 by flow cytometry.;Evaluation of oxidative stress indices. Timepoint: Beginning and end of the study. Method of measurement: Evaluation of serum level of total antioxidant capacity (TAC) and total oxidative capacity (TOC) by Kiazist diagnostic kits.;Evaluation of inflammatory indicators. Timepoint: Beginning and end of the study. Method of measurement: The inflammatory marker ESR is determined by sodium citrate anticoagulant and CRP by ELISA and commercial German LDN kit.;Quality of Life. Timepoint: Beginning and end of the study. Method of measurement: Quality of Life Questionnaire through HIV Disability Questionnaire (HDQ). | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of renal index. Timepoint: Beginning and end of the study. Method of measurement: Creatine test and BUN test are performed based on enzymatic method.;Evaluation of protein index. Timepoint: Beginning and end of the study. Method of measurement: Albumin levels are measured based on the Bromocresol Green test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactpayam tabarsi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed